Roche Pharma Deepens China Commitment with Over RMB 1.4 Billion Invested in Three Years and Unveils Global Launch Products at CIIE

ShanghaiOctober 10, 2022PR Newswire -- As the fifth China International Import Expo (hereinafter referred to as "CIIE") enters the countdown, Roche, which has participated in the CIIE for five consecutive years, announced an additional investment of nearly 250 million RMB in China, further increasing its commitment to the Chinese market. In the past three years, Roche Pharmaceuticals has invested more than 1.4 billion RMB and has great confidence in the Chinese market. Roche was one of the first Fortune 500 foreign companies to express support for and participate in the CIIE to the Ministry of Commerce, and is also the chairman unit of the Pharmaceutical Professional Committee of the CIIE Exhibitors Alliance. At this year's CIIE, Roche will present a leading global innovation matrix, demonstrating with concrete actions Roche’s ongoing commitment to the Chinese market and its confidence and promise to lead the future of health through innovation.

Firm Confidence in Deepening Commitment to China: Roche Pharma Surpasses Three-Year Milestone14Investment continues to increase

As China continues to promote high-level opening up and improve the business environment, these efforts have consistently injected a "strong stimulant" for multinational companies like Roche in their development within China. With the convening of the CIIE, an excellent platform for openness and showcasing, Roche has been continuously increasing its investment in China. Over the past three years, Roche Pharmaceuticals has invested more than 1.4 billion USD, taking concrete actions to practice the commitment of "Rooted in China, serving China.""The commitment. In 2019, an additional investment of 863 million RMB was made to upgrade the R&D center into the brand-new Roche Shanghai Innovation Center. In 2021, Roche China Accelerator was established with an investment of nearly 300 million RMB, aiming to accelerate the development of China's healthcare innovation and empower the construction of China's local healthcare innovation ecosystem. In 2022, an additional investment of nearly 250 million RMB was made as working capital to further increase investment in the Chinese market and accelerate benefits for Chinese patients. Meanwhile, the Roche Shanghai Innovation Center (RICS) was officially upgraded to the Roche China Innovation Center (CICoR), which has independent decision-making authority for new drug research and early development, continuously developing innovative medicines for patients in China and around the world.

Bringing Five New Global Product Launches to the CIIE, Accelerating Benefits for Chinese Patients

As one of the largest brands in the medical device and healthcare exhibition area, Roche will comprehensively showcase nearly 30 products covering multiple disease areas on its 1,000-square-meter booth this year.Innovative ProductsAmong them, in addition to several products that have already been launched in China,Product, it will also bring nearly 10 global innovative products that are about to be launched in China, covering major disease areas such as hematological oncology, breast cancer, ophthalmology, and neuroscience. As a leader in the field of hematology, Roche has a rich pipeline of hematology products. This time, it will bring several products that are about to be launched in China.New ProductAmong them, Polivy, the world's first ADC drug (antibody-drug conjugate) targeting CD79b, has experimental data surpassing the gold standard of first-line treatment for over 20 years, and is expected to revolutionize the treatment landscape of diffuse large B-cell lymphoma (DLBCL). Another innovative drug in the field of rare blood diseases, Crovalimab, is expected to become the first in the industry.Good morningInnovative drugs launched in Europe and the United States have achieved their first release in China, filling the treatment gap for Chinese patients with PNH. In the field of breast cancer, Roche will introduce Phesgo, the world's first subcutaneous combination regimen for HER2-positive breast cancer, which is about to be launched in China. It can be administered through a single subcutaneous injection, significantly reducing administration time and providing patients with a faster and less invasive new treatment option. Roche has always been committed to exploring groundbreaking therapies in ophthalmology, and at this CIIE, it will present Faricimab, the world’s first bispecific antibody in the ophthalmology field. It has already been approved for marketing in Europe and the United States and is regarded as the first treatment option with a novel mechanism of action in ophthalmology in over a decade.

President of Roche Pharmaceuticals China, Bian XinSaid: "Over the past five years, the CIIE has become a premier platform and gathering place for the global launch of innovative products and cutting-edge technologies, fully unleashing the powerful spillover effects of the CIIE. We have showcased more than 30 innovative products and new indications at the CIIE, nearly half of which have already entered China, benefiting Chinese patients. This year, we will present our full portfolio of marketed and soon-to-be launched products, world premieres, and innovative solutions at the CIIE to accelerate access for more Chinese patients. Over the past three years, Roche Pharmaceuticals has invested over 1.4 billion to expedite its innovation track in China, demonstrating strong confidence in the Chinese market, with plans to further increase investment in China in the future. Meanwhile, as the chairman unit of the Pharmaceutical Professional Committee of the CIIE Exhibitors Alliance, we hope to leverage the bridging effect of the CIIE, collaborate with the government and various partners to strengthen exchanges and cooperation, promote resource aggregation and industry development, and jointly build, create, and share in China's healthcare ecosystem."

China has always been an important part of Roche's global strategy. Adhering to the principle of "doing what patients need first," Roche Group's ties with China span over 90 years, during which it has consistently fulfilled its long-term commitment to China. Among large multinational pharmaceutical companies, Roche was the first to establish and continuously upgrade a complete pharmaceutical value chain in China, covering research, development, production, and marketing. At this year’s CIIE, Roche will comprehensively showcase multiple innovative achievements, including the significant strategic investment project "Roche China Accelerator," and will host several launch events for innovative solutions. In the future, Roche will continue to leverage the CIIE platform to accelerate the introduction of innovative drugs from around the world, collaborate with more partners to actively explore innovative healthcare solutions and cooperation models, and contribute to the early realization of the Healthy China 2030 goals.